A sensor and method for measuring bilirubin in a liquid sample are disclosed. The sensor comprises a substrate comprising a reservoir disposed within the substrate, the reservoir having a top surface and a bottom surface; a filter; at least one transparent portion, the transparent portion forming at least a part of the bottom surface of the reservoir, and a reflector comprising at least a portion of the reservoir. The method for measuring bilirubin in a liquid sample comprises inserting a sensor into an analyzer; introducing the liquid sample to the sensor; filtering the liquid sample such that the sample flows into a reservoir in the sensor; illuminating the liquid sample in the sensor using a light source in the analyzer; measuring a reflectance of the liquid sample at one or more wavelengths using a detector in the analyzer; and computing a measurement of bilirubin using the measured reflectances.

An example blood cell lysis composition includes a buffer and a secondary alcohol ethoxylate at a concentration in the range of about 2.5 percent (%) to about 20% weight per volume (w/v). The secondary alcohol ethoxylate may include Tergitol TMN-100X or Tergitol 15-S-9. The composition may be configured to lyse at least 90% of blood cells in a blood sample.

Fluorescent proteins (Chlopsid FP I from Kaupichthys hyoproroides and Chlopsid FP II from Kaupichthys n. sp.) are used in a method for detecting bilirubin. The proteins are based on transcriptome analysis of the false moray eels, Kaupichthys hyoproroides and Kaupichthys n. sp., the later representing a heretofore undescribed species.

Identification and use of proteins fluorescently labeled and that undergo a change in fluorescence index upon binding bilirubin are described. Probes are disclosed which are labeled at a cysteine or lysine residue and also probes labeled at both cysteine and lysine with two different fluorophores. These probes are useful for determination of unbound bilirubin levels in a fluid sample.

Methods and systems are disclosed including a reagent analyzer, comprising a test analyzing mechanism, such as an optical imaging system, configured to read a first sample of a specimen combined with a reagent configured to react with the sample in a presence of an analyte of interest and a second sample of the specimen that is not combined with a reagent, and to output one or more first signals indicative of the test analyzing mechanism reading the first and second samples; and a processor receiving the one or more first signals and executing logic to analyze the second sample responsive to the processor determining that the analyte of interest is present in the first sample. The processor may execute logic to analyze the second specimen utilizing one or more ratio algorithm and comparing the results of the algorithm against predetermined values indicative of expected color.

A method of determining a level of interference with a photometric in-vitro diagnostic assay and an in-vitro diagnostic analyzer for carrying out the method are described. An aliquot of a sample is treated with at least one reagent to obtain a sample/reagent mixture and subjecting the sample/reagent mixture to a photometric measurement in order to obtain a result of the in-vitro diagnostic assay, and during the same photometric measurement determining a preliminary level of interference by semi-quantitatively determining one or more interfering substances in the same sample/reaction mixture. A separate photometric measurement of another aliquot of the same sample either undiluted or diluted with a liquid other than a reagent is triggered in order to determine an effective level of interference by quantitatively determining the one or more interfering substances, only upon determining a preliminary level of interference above a predetermined threshold.

The present disclosure relates to methods for identifying a subject as eligible for treatment with lanifibranor, methods for treating a subject suffering from liver disease comprising administering lanifibranor to said subject and monitoring a subject's risk of experiencing a side effect caused by lanifibranor treatment.

The present invention provides diagnostic and/or prognostic markers indicative of liver fat, fatty liver diseases (e.g. non-alcoholic fatty liver disease (NAFLD) and/or hepatocellular cancer deriving from liver fat.

The invention relates generally to biochemical assays and more particularly to digital microfluidics multi-dynamic range parallel biochemical assays. The invention provides methods that enable improved precision and linearity for digital microfluidics analyses (i.e., analyses performed on a droplet actuator using droplet operations), including for example, assays related to measuring analytes in a biological sample. Examples of assays that may be performed using a method of the invention include measuring analytes in blood, including analytes from blood components, such as analytes present in plasma. The invention provides a digital microfluidics device (or cartridge) and methods for performing a biochemical assay using the microfluidics device to measure an analyte in a sample.